Cargando…
Consecutive Aromatic Residues Are Required for Improved Efficacy of β-Sheet Breakers
Alzheimer’s disease is a fatal neurodegenerative malady which up to very recently did not have approved therapy modifying its course. After controversial approval of aducanumab (monoclonal antibody clearing β-amyloid plaques) by FDA for use in very early stages of disease, possibly new avenue opened...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102079/ https://www.ncbi.nlm.nih.gov/pubmed/35563639 http://dx.doi.org/10.3390/ijms23095247 |